• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Creative Medical Technology Holdings, Inc. - Common Stock (NQ:CELZ)

1.800 -0.050 (-2.70%)
Streaming Delayed Price Updated: 11:25 AM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Creative Medical Technology Holdings, Inc. - Common Stock

News headline image
Creative Medical Technology Holdings Provides Corporate Update
March 27, 2024
From Creative Medical Technology Holdings, Inc.
Via Business Wire
Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA
March 08, 2024
Via AB Newswire
News headline image
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
March 07, 2024
From Creative Medical Technology Holdings, Inc.
Via Business Wire
News headline image
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
March 06, 2024
From Creative Medical Technology Holdings, Inc.
Via Business Wire
News headline image
What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?
August 24, 2023
Via ACCESSWIRE
News headline image
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
December 20, 2023
Via ACCESSWIRE
News headline image
Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update
July 13, 2023
Via ACCESSWIRE
News headline image
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
March 07, 2023
From Creative Medical Technology Holdings, Inc.
Via Business Wire
News headline image
Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects
February 14, 2023
From Creative Medical Technology Holdings, Inc.
Via Business Wire
InvestorNewsBreaks – Creative Medical Technology (NASDAQ: CELZ) Expects $17 Million Gross Proceeds from Private Placement
May 16, 2022
Via Investor Brand Network
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
March 24, 2022
Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor... 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap